Response of children with Turner syndrome with different types of karyotype abnormalities to growth hormone treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Short stature is the main characteristic of Turner syndrome (TS) patients and growth hormone (GH) therapy has been essential for achieving the final adult height (Ht). In the present study, the response of TS patients with different types of karyotype abnormalities to GH therapy was analyzed.Methods: The clinical parameters of 194 TS patients registered in the LG Growth Study were retrospectively reviewed. Data for 4 groups of subjects were obtained as follows: monosomy X (n=56); X structural abnormality (n=26); X mosaicism without structural abnormality (n=41); X mosaicism with structural abnormality (n=71). Clinical characteristics and growth response parameters were compared over 3 years of GH treatment.Results: The baseline Ht standard deviation score (SDS) of all patients was -2.85±0.86. The baseline Ht SDS, body mass index SDS, and chronological age (years)-bone age (years) were significantly different based on chromosomal abnormalities. The growth velocity (GV; cm/yr) in the first year was the highest and significantly different among the groups. The GV in the second year also showed an increase in the X mosaicism without structural abnormality group compared with the monosomy X group. The change in Ht SDS (ΔHt SDS) over 3 years was not statistically different between karyotypes.Conclusion: The response to 3 years of GH therapy did not differ based on the karyotype of TS patients although the initial Ht SDS was the lowest in the monosomy X group.
Abstract
Purpose: Short stature is the main characteristic of Turner syndrome (TS) patients and growth hormone (GH) therapy has been essential for achieving the final adult height (Ht). In the present study, the response of TS patients with different types of karyotype abnormalities to GH therapy was analyzed.Methods: The clinical parameters of 194 TS patients registered in the LG Growth Study were retrospectively reviewed. Data for 4 groups of subjects were obtained as follows: monosomy X (n=56); X structural abnormality (n=26); X mosaicism without structural abnormality (n=41); X mosaicism with structural abnormality (n=71). Clinical characteristics and growth response parameters were compared over 3 years of GH treatment.Results: The baseline Ht standard deviation score (SDS) of all patients was -2.85±0.86. The baseline Ht SDS, body mass index SDS, and chronological age (years)-bone age (years) were significantly different based on chromosomal abnormalities. The growth velocity (GV; cm/yr) in the first year was the highest and significantly different among the groups. The GV in the second year also showed an increase in the X mosaicism without structural abnormality group compared with the monosomy X group. The change in Ht SDS (ΔHt SDS) over 3 years was not statistically different between karyotypes.Conclusion: The response to 3 years of GH therapy did not differ based on the karyotype of TS patients although the initial Ht SDS was the lowest in the monosomy X group.
참고문헌 (30)
- Park HK, "Responses to three years of growth hormone therapy in girls with turner syndrome", Ann Pediatr Endocrinol Metab, 18, pp.13~18 (2013)
- Li P, "Height outcome of the recombinant human growth hormone treatment in Turner syndrome : a meta-analysis", Endocr Connect, 7, pp.573~583 (2018)
- Child CJ, "Radiological features in patients with short stature homeobox-containing(SHOX)gene deficiency and Turner syndrome before and after 2 years of GH treatment", Horm Res Paediatr, 84, pp.14~25 (2015)
- Woelfle J, "Secular trends on birth parameters, growth, and pubertal timing in girls with Turner syndrome", Front Endocrinol(Lausanne), 9, pp.54~ (2018)
- Fiot E, "X-chromosome gene dosage as a determinant of impaired pre and postnatal growth and adult height in Turner syndrome", Eur J Endocrinol, 175, pp.X1~ (2016)
- Stephure DK, "Impact of growth hormone supplementation on adult height in turner syndrome : results of the Canadian randomized controlled trial", J Clin Endocrinol Metab, 90, pp.3360~3366 (2005)
- Davenport ML, "Growth hormone treatment of early growth failure in toddlers with Turner syndrome : a randomized, controlled, multicenter trial", J Clin Endocrinol Metab, 92, pp.3406~3416 (2007)
- Ranke MB, "Analyses from a centre of short-and longterm growth in Turner's syndrome on standard growth hormone doses confirm growth prediction algorithms and show normal IGF-I levels", Horm Res Paediatr, 77, pp.214~221 (2012)
- Isojima T, "Trends in age and anthropometric data at start of growth hormone treatment for girls with Turner syndrome in Japan", Endocr J, 55, pp.1065~1067 (2008)
- Jung MK, "Machine learning-based prediction of response to growth hormone treatment in Turner syndrome : the LG Growth Study", J Pediatr Endocrinol Metab, 33, pp.71~78 (2020)
- van Pareren YK, "Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens", J Clin Endocrinol Metab, 88, pp.1119~1125 (2003)
- Wu HH, "Karyotype classification, clinical manifestations and outcome in 124 Turner syndrome patients in China", Ann Endocrinol(Paris), 80, pp.10~15 (2019)
- Gravholt CH, "The changing face of Turner syndrome. The changing face of Turner syndrome", Endocr Rev, 44, pp.33~69 (2023)
- Fiot E, "Turner syndrome : French National Diagnosis and Care Protocol(NDCP; National Diagnosis and Care Protocol", Orphanet J Rare Dis, 17(Suppl 1), pp.261~ (2022)
- Chung SJ, "Design of the long-term observational cohort study with recombinant human growth hormone in Korean children : LG Growth Study", Ann Pediatr Endocrinol Metab, 23, pp.43~50 (2018)
- Kim JH, "The 2017 Korean National Growth Charts for children and adolescents : development, improvement, and prospects", Korean J Pediatr, 61, pp.135~149 (2018)
- Hyun SE, "Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3in Korean children and adolescents", Clin Biochem, 45, pp.16~21 (2012)
- Kasprzyk J, "Karyotype abnormalities in the X chromosome predict response to the growth hormone therapy in Turner syndrome", J Clin Med, 10, pp.5076~ (2021)
- Gravholt CH, "Clinical practice guidelines for the care of girls and women with Turner syndrome : proceedings from the 2016 Cincinnati International Turner Syndrome Meeting", Eur J Endocrinol, 177, pp.G1~70 (2017)
- Cameron-Pimblett A, "The Turner Syndrome Life Course Project : karyotype-phenotype analyses across the lifespan", Clin Endocrinol(Oxf), 87, pp.532~538 (2017)
- Yeo CY, "Clinical disease characteristics according to karyotype in Turner syndrome", Clin Exp Pediatr, 53, pp.158~162 (2010)
- Al Shaikh A, "Effect of growth hormone treatment on children with idiopathic short stature(ISS), idiopathic growth hormone deficiency(IGHD), small for gestational age(SGA)and Turner syndrome(TS)in a tertiary care center", Acta Biomed, 91, pp.29~40 (2020)
- Sas TC, "Normalization of height in girls with Turner syndrome after long-term growth hormone treatment : results of a randomized dose-response trial", J Clin Endocrinol Metab, 84, pp.4607~4612 (1999)
- van Pareren YK, "Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens", J Clin Endocrinol Metab, 88, pp.1119~1125 (2003)
- Hasegawa Y, "Gradually increasing ethinyl estradiol for Turner syndrome may produce good final height but not ideal BMD", Endocr J, 64, pp.221~227 (2017)
- Ross JL, "Growth hormone plus childhood low-dose estrogen in Turner’s syndrome", N Engl J Med, 364, pp.1230~1242 (2011)
- Lanes R, "Near adult height in girls with Turner syndrome treated with growth hormone following either induced or spontaneous puberty", J Pediatr, 212, pp.172~179 (2019)
- Clayton P, "A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome", Eur J Endocrinol, 169, pp.277~289 (2013)
- Yoon JY, "Response to growth hormone according to provocation test results in idiopathic short stature and idiopathic growth hormone deficiency", Ann Pediatr Endocrinol Metab, 27, pp.37~43 (2022)
- Shin CW, "Short-term effect of growth hormone treatment in childhood leukemia survivors with growth hormone deficiency", Ann Pediatr Endocrinol Metab, 28, pp.116~123 (2023)